Please select the option that best describes you:
Would you extrapolate results from ELEVATE-RR study to favor use of acalabrutinib as first-line therapy in treatment-naive CLL?
Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?
Answer from: Medical Oncologist at Academic Institution
The ELEVATE-RR study enrolled patients with a median of 2 prior regimens, with either deletion 11q or deletion 17p. I think one could debate whether selecting this patient population as compared to a less selected treatment naïve population would be more likely to find a difference between the ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Yes, I feel comfortable extrapolating these data to the frontline setting. This is primarily because we have multiple studies of acalabrutinib as well as ibrutinib in the frontline setting where the PFS estimates at various timepoints are similar.
Comments
Medical Oncologist at Columbia University Medical Center
I am also in agreement - although ELEVATE-RR was i...
I am also in agreement - although ELEVATE-RR was i...
Answer from: Medical Oncologist at Academic Institution
While the study did not compare untreated CLL patients, ELEVATE-RR showed higher cardiovascular events that over the long-term could negatively influence outcome even more than in the up-front rather than the relapse setting where drug exposure is shorter. As such, as both a monotherapy and combinat...